Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.480
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
285,742
Open
1.490
Bid (Size)
1.470 (6)
Ask (Size)
1.570 (2)
Prev. Close
1.480
Today's Range
1.470 - 1.530
52wk Range
1.025 - 2.850
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
Performance
YTD
-12.43%
-12.43%
1 Month
+11.28%
+11.28%
3 Month
-20.00%
-20.00%
6 Month
-12.94%
-12.94%
1 Year
-28.50%
-28.50%
More News
Read More
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
July 08, 2024
Via
InvestorPlace
3 Psychedelic Stocks to Ride to the Moon and Beyond
July 06, 2024
Via
InvestorPlace
Exposures
Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
July 03, 2024
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Via
Talk Markets
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
June 26, 2024
From
atai Life Sciences
Via
GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Via
Talk Markets
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
June 20, 2024
From
atai Life Sciences
Via
GlobeNewswire
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
June 09, 2024
Via
Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
June 05, 2024
Via
Benzinga
Exposures
Product Safety
What's Going On With MindMed And Psychedelic Stocks?
June 05, 2024
Via
Benzinga
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024
From
atai Life Sciences
Via
GlobeNewswire
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
May 23, 2024
From
atai Life Sciences
Via
GlobeNewswire
ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
May 15, 2024
From
atai Life Sciences
Via
GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
May 09, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
Via
Talk Markets
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
April 24, 2024
From
atai Life Sciences
Via
GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
Via
Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
April 19, 2024
Via
Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
April 17, 2024
From
atai Life Sciences
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.